Skip to content
Study details
Enrolling now

A Study Utilizing Escitalopram in Glioma Patients

University of Nebraska
NCT IDNCT03728673ClinicalTrials.gov data as of Apr 2026
Phase

Phase 2

Target enrollment

20

Study length

about 8.5 years

Ages

19+

Locations

1 site in NE

What this study is about

Researchers are testing whether escitalopram, an oral medication, can improve cognitive function in adults with newly diagnosed grade IV glioma. The trial will last for approximately 3100 days and involve around 20 participants.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Take Escitalopram Oral Capsules

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Oral

How treatment is administered

Treatment Assignment
All receive treatment

Everyone gets the investigational treatment.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Drug classes

escitalopram (SSRI; increases serotonin availability)

Drug routes

oral (Oral Tablet)

Endpoints

Primary: Change in Psycho-social Functions - PROMIS Neuro-QoL Item Bank v1.0 - Anxiety, Change in Psycho-social Functions - PROMIS Neuro-QoL Item Bank v1.0 - Depression, Change in Psycho-social Functions - PROMIS Neuro-QoL Item Bank v1.0 - Fatigue

Body systems

Neurology